A Study of the Preliminary Efficacy of DARE-HPV to Treat High-risk Persistent Human Papillomavirus (hrHPV)
for Human Papilloma Virus (HPV)
3 locations incl. Phoenix
Sponsor: Daré Bioscience, Inc.
Sex: Female·Age: 22 - 50
Code: NCT07601074·Phase 2·Not Yet Recruiting·Listed May 2026